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Abstract
Background: To evaluate the economic implications of the pre-emptive use of extracorporeal carbon dioxide
removal (ECCO2R) to avoid invasive mechanical ventilation (IMV) in patients with hypercapnic ventilatory
insufficiency failing non-invasive ventilation (NIV).
Methods: Retrospective ancillary cost analysis of data extracted from a recently published multicentre case–control-study
(n = 42) on the use of arterio-venous ECCO2R to avoid IMV in patients with acute on chronic ventilatory failure. Cost
calculations were based on average daily treatment costs for intensive care unit (ICU) and normal medical wards as well
as on the specific costs of the ECCO2R system.
Results: In the group treated with ECCO2R IMV was avoided in 90 % of cases and mean hospital length of stay (LOS) was
shorter than in the matched control group treated with IMV (23.0 vs. 42.0 days). The overall average hospital treatment
costs did not differ between the two groups (41.134 vs. 39.366 €, p = 0.8). A subgroup analysis of patients with chronic
obstructive pulmonary disease (COPD) revealed significantly lower median ICU length of stay (11.0 vs. 35.0 days), hospital
length of stay (17.5 vs. 51.5 days) and treatment costs for the ECCO2R group (19.610 vs. 46.552 €, p = 0.01).
Conclusions: Additional costs for the use of arterio-venous ECCO2R to avoid IMV in patients with acute-on-chronic
ventilatory insufficiency failing NIV may be offset by a cost reducing effect of a shorter length of ICU and hospital stay.
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Background
Over the last decades invasive mechanical ventilation
(IMV) is increasingly applied to critically ill patients of
a more and more ageing and comorbid population [1].
At the same time the negative side effects of IMV, such
as ventilator-associated lung injury (VILI), ventilator-
associated pneumonia (VAP), or ventilator-associated
diaphragmatic dysfunction (VIDD) are recognised to
contribute to morbidity and mortality [2–4]. In the last
decade severe respiratory failure is increasingly treated
with extracorporeal lung support, both for oxygenation
(ECMO) and for carbon dioxide removal (ECCO2R) [5].
Recently, a new strategy of applying ECCO2R to avoid
IMV and its side-effects in patients with hypercapnic
acute-on-chronic ventilatory failure not responding to
non-invasive ventilation (NIV) has been described [6–10].
The most common condition of acute-on-chronic ventila-
tory failure frequently leading to ICU admissions is an
acute exacerbation of a chronic obstructive pulmonary
disease (COPD) [11]. Once IMV is commenced after fail-
ure of NIV, especially patients with chronic pulmonary
disease carry an increased risk of prolonged weaning and
length of ICU stay and their overall prognosis deteriorates
[12–18].
Our research group has recently published a matched
case–control study on the feasibility and safety of ECCO2R
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in patients with NIV refractory acute on chronic hypercap-
nic ventilatory failure to avoid intubation [7]. The under-
lying chronic lung diseases of the study group are shown
in Table 1. The extracorporeal device used was the so-
called “interventional lung assist” (iLA®, Novalung GmbH,
Heilbronn, Germany), a pumpless, arterio-venous circuit
for ECCO2R (av-ECCO2R), which has been licensed in
2006 [19] and since then been applied worldwide to ap-
proximately 10.000 patients [20]. Figure 1 shows the
clinical setup of the system (Fig 1). Further details are
described elsewhere [19].
Intubation was avoided in 19 of 21 patients (90 %) treated
with av-ECCO2R. Two patients in the av-ECCO2R group
(9.5 %) had major bleeding complications. Ventilator-
associated complications, such as VILI, VAP and VIDD,
could not be recorded for methodological reasons. The me-
dian duration of av-ECCO2R support and mechanical ven-
tilation in the av-ECCO2R group was 9 days (range 1–116)
and the median duration of mechanical ventilation in the
control group was 21 days (range 1–47; p = 0.944). Length
of stay (LOS) in the ICU and in hospital was shorter in the
av-ECCO2R group than that of the matched control group
treated with invasive mechanical ventilation (15 vs. 30 days
for LOS in ICU; p = 0.26, and 23 vs. 42 days for LOS in
hospital; p = 0.05). Six month mortality was 33 % in both
groups.
Despite its increasing use, nothing is known about the
economic impact of the use of this complex and costly
technology to avoid intubation and IMV. Thus the pur-
pose of this ancillary economic analysis was to evaluate
if the reduction in hospital length of stay also translated
to reduced treatment costs.
Methods
Clinical study design and setting
This ancillary retrospective economic evaluation was
undertaken using data from a recently published multi-
centre case–control-study on the use of an arterio-
venous extracorporeal carbon dioxide removal device
(av-ECCO2R) to avoid invasive mechanical ventilation
in patients with acute on chronic respiratory insufficiency
failing NIV [7]. The original study was conducted in four
tertiary level hospitals in Germany (Department of
Intensive Care Medicine, University Medical Center
Hamburg-Eppendorf; Department of Internal Medicine,
Infectious Diseases and Respiratory Medicine, Charité-
Universitaetsmedizin Berlin; Department of Medicine
III, University of Halle (Saale); Department of Cardiology
and Intensive Care, Klinikum Bogenhausen, Munich).
The data collected in the case–control-study were rou-
tine clinical data from medical records. Because of the
retrospective study design patient consent to partici-
pate in the study was not applicable. The institutional
ethics committees of all four participating centres ap-
proved anonymised data collection and analyses.
Patients and interventions
In 21 non-intubated patients with acute on chronic hyper-
capnic respiratory failure not responding to NIV and fulfill-
ing criteria for intubation the iLA® device for ECCO2R had
been commenced in order to avoid imminent intubation.
All of these patients had potentially reversible respiratory
failure, e.g. acute exacerbation of COPD, and endotracheal
intubation was deemed to carry a substantial risk of sec-
ondary complications due to prolonged invasive mechan-
ical ventilation. All av-ECCO2R circuits were inserted at
the bed-side in the ICU by the attending intensivists. The
study centers matched control patients had also been ad-
mitted with hypercapnic acute-on-chronic ventilatory fail-
ure but in contrast were intubated and placed on invasive
mechanical ventilation after NIV failure. The matching
criteria for the control group selection were: 1) underlying
diagnosis, 2) age, 3) simplified acute physiology score
(SAPS-2), and 4) arterial pH before ECCO2R or intubation
[7]. All control patients underwent daily awakening and
spontaneous breathing trials for ventilatory weaning ac-
cording to the local protocol.
Table 1 Diagnoses of chronic respiratory diseases
Diagnosis av-ECCO2R group MV group
n (%) n (%)
Severe COPD 14 (66.7) 14 (66.7)
Cystic fibrosis 2 (9.5) 2 (9.5)
Pulmonary Graft-vs-Host-Disease 2 (9.5) 2 (9.5)
Pulmonary fibrosis 1 (4.8) 1 (4.8)
Bronchial asthma 1 (4.8) 1 (4.8)
Pneumonia post lung transplant 1 (4.8) 1 (4.8)
Fig. 1 Clinical setup and components of the pumpless, arterio-venous
ECCO2R circuit “interventional lung assist” (iLA®, Novalung GmbH,
Heilbronn, Germany). The patient has given written consent for
publication of this picture. 1 = arterial cannula, 2 = venous cannula,
3 = circuit including membrane for ECCO2R, 4 = sweep gas (O2),
5 = ultrasonic flow-meter
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In addition to the economic evaluation of all 21 cases
and their matched controls two subgroups were further
analysed: The first subgroup was limited to those 17
ECCO2R cases and their corresponding controls, which
subsequently were not lung transplanted. Because no
control patient underwent lung transplantation costs
were deemed not to be more comparable in this sub-
group analysis. The second subgroup was further limited
to all 12 cases with COPD not undergoing lung trans-
plantation and their matched controls. The rationale
for this was to evaluate a homogeneous patient group
with the most common underlying diagnosis for acute
on chronic ventilatory failure.
Cost analysis
The costs were analysed from the hospital’s perspective
and only direct treatment costs were evaluated [21]. All
costs are expressed in 2013 Euro. Calculation of overall
hospital costs for each case and control was based on
average daily costs for treatment in the ICU and the
medical normal ward. Average daily ICU costs were
based on the results from the largest dataset on German
national average daily ICU costs published by Moerer
et al. [22]. Costs were derived from results of their sub-
group analysis on patients on mechanical ventilation
treated in tertiary level hospitals [22]. These costs in-
cluded both variable and fixed costs. All costs derived in
this study were 2003 Euros and were subsequently ad-
justed for the corresponding yearly inflation rates from
2004 until 2014, ranging from 0.3 to 2.6 % according to
the German Federal Statistics Office [23].
Average daily costs for treatment in the normal medical
ward were derived from the 2013 cost calculations of the
study centres administrative data. These costs also in-
cluded both variable and fixed costs. Applied average daily
costs for ICU treatment and treatment on the medical
ward are shown in Table 2.
In addition, specific costs for av-ECCO2R treatment
were calculated for each case based on the actual util-
isation of consumables (cannulas and membranes) and
length of treatment (daily rental costs for ultrasonic
flow meter) (Fig. 1). Costs for consumables and daily
rental costs for the flow meter were based on the man-
ufacturer’s official list prices for Germany in 2013. All
cost items for av-ECCO2R and their prices are listed in
Table 2. Any specific costs for mechanical ventilation
were subsumed in the average daily ICU costs as de-
rived in the original study by Moerer et al. [22].
ICU treatment costs for each case and control were
calculated by multiplying the average daily ICU costs by
the number of days spent in the ICU. In the case group
specific costs for av-ECCO2R treatment were added to
the ICU costs. Costs for treatment on the normal wards
were calculated by multiplying average daily costs for a
normal medical ward with the number of days actually
spent on the normal ward after ICU discharge until hos-
pital discharge or death. Finally, treatment costs for ICU
and the normal ward were added to estimate the total
hospital treatment costs.
To test the robustness of these cost estimates and to as-
sess the impact of variations of daily ICU and normal ward
costs, sensitivity analyses were performed. Average daily
ICU costs calculated by Moerer et al. [22] were varied by
applying the corresponding upper and lower standard devi-
ations. Average daily costs for normal medical wards were
varied by 30 %. Upper and lower margins for average daily
treatment costs are presented in Table 2.
Diagnosis-related groups (DRG) and specific reimburse-
ment plans for mechanical ventilation and extracorporeal
lung support were not analysed.
Statistical methods
Results are presented as absolute numbers and percentages,
as means with standard deviations for continuous variables
if normally distributed, and as medians with ranges if not
normally distributed. Comparisons between the two groups
were performed using the t-test or the Mann–Whitney U
test depending on the data distribution. Two-sided p < 0.05
values were considered significant. The software used was
SPSS® (version 20.0, SPSS Inc., Chicago, IL, USA).
Results
Median hospital length of stay (LOS) was shorter in the
av-ECCO2R group than in the matched control group
treated with IMV (23 vs. 42 days, p = 0.05). The overall
mean hospital treatment costs did not differ significantly
between the two groups (41.134 vs. 39.366 €, p = 0.80). A
sensitivity analysis did not reveal any significant differ-
ences when applying higher margins (53.689 vs. 54.155 €,
p = 0.98) or lower margins (28.616 vs. 24.629 €, p = 0.60).
Average ICU costs of the av-ECCO2R and the control
Table 2 Values used for cost model
Item Value
(Euro)






• Daily costs for ICU 1115 697 1534




• Single cannula 458 - -
• Set with tubing and
Novalung-Membrane
2335 - -
• Daily rental costs for
ultrasonic flow-meter
62/day - -
Abbreviations: ICU = intensive care unit, ECCO2R = Extracorporeal carbon
dioxide removal
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group were 38.459 € (93.5 % of all hospital costs) and
33.290 € (84.6 % of all hospital costs), respectively. Aver-
age costs for av-ECCO2R, included in the ICU costs of the
case group, were 7.717 € (18.8 %).
In the subgroup of 17 cases and controls without lung
transplantation 6-months mortality rates were 41.2 and
35.3 % respectively (p = 1.0). The median hospital LOS
and ICU-LOS were 22 vs. 42 days (p = 0.41) and 13 vs.
30 days (p = 0.23). Overall mean hospital treatment costs
did not differ significantly between av-ECCO2R cases and
controls (33.843 vs. 39.731 €; p = 0.64) and a sensitivity
analysis did not change these non-significant differences.
A subgroup analysis of each 12 non-lung-transplanted
COPD cases and their matched COPD controls revealed
no significant differences in 6-months mortality (33.3 % vs.
25.0 %; p = 1.0). Hospital LOS (17.5 vs. 51.0 days; p = 0.01)
and ICU-LOS (11.0 vs. 35.0 days; p = 0.01) were signifi-
cantly shorter in the av-ECCO2R group. Mean hospital
treatment costs were also significantly lower in the
ECCO2R group compared to the control group (19.610
vs. 46.552 €, p = 0.01; 95 % confidence interval (95%CI)
of absolute cost difference 5.769–48.113 €). A sensitiv-
ity analysis also showed significant differences. Detailed
results of all groups and subgroups are presented in
Table 3.
Discussion
This study is the first economic evaluation to compare the
costs of an av-ECCO2R strategy to avoid IMV with costs
for a conventional strategy of IMV after NIV failure in pa-
tients with acute-on-chronic ventilatory insufficiency. The
overall hospital costs did not differ significantly between
the av-ECCO2R group and the matched control group
(53.689 vs. 54.155 €) despite additional average costs of
7717 € per av-ECCO2R treatment. This did not change
after excluding four ECCO2R patients who underwent
lung transplantation and their controls. Thus, in this study
the extra costs for av-ECCO2R treatment were offset by
lower hospital costs due to shorter average hospital length
of stay in the av-ECCO2R group. A short length of stay in
the ICU may per se result in a reduction of treatment
costs, as it has previously been shown that length of ICU
stay explains approximately 85 to 90 % of interpatient
variation in hospital costs [24].
Analysis of all COPD patients, the biggest and most
homogenous diagnostic subgroup, revealed significantly
lower overall hospital treatment costs in the av-ECCO2R
group (19.610 vs. 46.552 €) suggesting that ECCO2R to
avoid intubation in patients with AECOPD and NIV fail-
ure may lead to a reduction of overall treatment costs.
The potential economical relevance of this hypothesis is
augmented by the fact that COPD has a high prevalence
projected to be the fifth leading burden of disease world-
wide by the year 2020 [11, 25].
Micro-costing was used for cost calculation of material
consumption for av-ECCO2R. Itemised cost evaluation
of all other treatment costs was not feasible due to the
retrospective study design. Instead, further cost analysis
was performed by means of macro-costing. Average daily
costs for ICU treatment used for cost analysis in this
study were based on a previous study by Moerer et al.
who calculated the average daily ICU costs in Germany
by cost analyses of 51 German ICUs [22]. Their calcula-
tions included both variable and fixed costs as were
costs for IMV. However, many health economic studies
have demonstrated that fixed costs, especially staffing
costs, account for up to 65 % of all treatment costs [22,
26–29]. Thus variation of variable costs probably has a
smaller effect of overall treatment costs. Moreover, sen-
sitivity analysis did not change the results suggesting a
degree of robustness of the results.
The rationale for applying the above mentioned data on
average ICU costs also to ECCO2R patients despite the fact
that the majority this group were not intubated and mech-
anically ventilated was, that from the experience of the par-
ticipating study centres staff resource utilisation for
management of invasive MV and av-ECCO2R with or with-
out non-invasive ventilation is comparable. In addition,
costs for material consumption from MV were proposed
to be relatively low and not significantly contributing to
the overall treatment costs. Costs for treatment of side ef-
fects of av-ECCO2R observed in the original case–control
study, such as bleeding and vascular surgery in one case,
were not itemised separately. These costs were included in
the average daily ICU costs as were treatment costs in the
control group for side effects caused by invasive MV, such
as treatment of ventilator-induced pneumonia. There is
evidence that costs for patients on MV are significantly
higher than costs for non-ventilated patients in ICU [22,
30, 31] and that COPD patients on invasive mechanical
ventilation have a longer stay in ICU and require higher
treatment efforts than non-COPD patients on MV [32].
These data may further justify subsuming costs for side ef-
fects of av-ECCO2R into average daily ICU costs and may
even suggest that a potential cost saving effect of avoiding
MV with its complications and associated costs by applying
av-ECCO2R may have been underestimated. On the other
hand, additional costs for complications caused by av-
ECCO2R may also be associated with significant costs. The
incidence of major, potentially costly complications was
low in the av-ECCO2R group (9.5 %), but may have been
underestimated because of low case numbers. Excluding 4
case-controls where the av-ECCO2R cases subsequently
underwent lung transplantation with potentially higher
costs did not change the results.
Since there are no valid national data on average
daily costs for treatment of patients on normal wards
in Germany who have previously been in ICU with
Braune et al. BMC Anesthesiology  (2015) 15:160 Page 4 of 7
respiratory failure, estimating these costs was based on
the study centres local average cost calculations. These lo-
cally derived calculations may be less generalizable. How-
ever, as only less than 25 % of the total hospital costs were
attributable to treatment on the normal ward, this poten-
tial error may be negligible.
This relationship is in line with findings of other studies
that have shown that length of ICU stay was the main de-
terminant of overall hospital cost variations [24, 33]. Again,
sensitivity analysis had no significant effect on the results
of this cost comparison.
Since cost calculations for ECCO2R were based on the
pumpless arterio-venous ECCO2R device applied in the
original study, these results cannot directly be applied to
veno-venous, pump-driven devices for ECCO2R since their
technology is more complex and extra cost apply for more
expensive circuits and consoles. In addition, the clinical
characteristics of patients and their controls of this study
Table 3 Comparisons of LOS and costs with sensitivity analysis and subgroup analysis
All study patients
Variable ECCO2R Control p value
Days [range] or Euro [SD] (n = 21) (n = 21)
Median length of stay in ICU 15 [4–137] 30 [4–66] 0.58
Median length of stay in hospital 23 [4–137] 42 [4–248] 0.05
Median duration of invasive MV 0 [0–47] 21 [4–47] <0.001
Mean costs for ECCO2R 7717 [7835] - -
Mean total ICU costs 38460 [43878] 33291 [22572] 0.63
Mean total hospital costs 41134 [43005] 39366 [29903] 0.88
Mean hospital costs with maximal values 53689 [56406] 54155 [41133] 0.98
Mean hospital costs with minimal values 28616 [18721] 24629 [18721] 0.61
Subgroup analysis after exclusion of patients with lung transplantation
Variable ECCO2R Control p value
Days [range] or Euro [SD] (n = 17) (n = 17)
Median length of stay in ICU 13 [4–137] 30 [4–66] 0.41
Median length of stay in hospital 22 [4–137] 42 [4–248] 0.23
Median duration of invasive MV 0 [0–47] 21 [1–47] 0.001
Mean costs for ECCO2R 5972 [6522] - -
Mean total ICU costs 24989 [35273] 33581 [23656] 0.41
Mean total hospital costs 33843 [40866] 39731 [31507] 0.64
Mean hospital costs with maximal values 44314 [53924] 54656 [43340] 0.54
Mean hospital costs with minimal values 23405 [27856] 24857 [19727] 0.86
Subgroup analysis of patients with COPD
Variable ECCO2R Control p value
Days [range] or Euro [SD] (n = 12) (n = 12)
Median length of stay in ICU 11 [4–23] 35 [4–66] 0.004
Median length of stay in hospital 17 [4–43] 51 [4–248] 0.04
Median duration of invasive MV 0 [0–22] 27 [4–47] 0.001
Mean costs for ECCO2R 4472 [1269] - -
Mean total ICU costs 13194 [4611] 39304 [25163] 0.004
Mean total hospital costs 19610 [7509] 46552 [34558] 0.02
Mean hospital costs with maximal values 25298 [10115] 64040 [47536] 0.01
Mean hospital costs with minimal values 13942 [4938] 29124 [21641] 0.03
Abbreviations: LOS length of stay, SD standard deviation, COPD chronic obstructive pulmonary disease, ICU intensive care unit, MV mechanical ventilation, ECCO2R
Extracorporeal carbon dioxide removal
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are quite specific as they had actually failed NIV and all
patients in the control group had been intubated. There-
fore they differ from the population of a recently published
case–control-study in which patients at risk of NIV failure
where treated with ECCO2R to avoid intubation [10]. In
this study 25 patients treated with NIV and in addition a
veno-venous, pump-driven ECCO2R device revealed a sig-
nificantly lower intubation rate in comparison to their 21
controls treated with NIV alone (12 % vs. 33 %). The LOS
in ICU and hospital did not differ significantly between the
two groups (8 vs. 12 and 24 vs. 22, respectively).
Further, this cost analysis did not take into account the
health care provider’s perspective on reimbursement plans,
because aspects of diagnosis-related groups (DRG) or spe-
cific reimbursements for costly treatments and procedures
such as invasive mechanical ventilation and extracorporeal
lung support were not addressed. The rational for this was
that reimbursement plans are individually negotiated be-
tween health care providers and healthcare payers on a
local, regional and/or national level. Reimbursements do
not necessarily represent factual costs and are highly vari-
able between health care systems and over time [31, 34]. In
fact, successfully avoiding intubation and MV by means of
ECCO2R paradoxically may lead to an economic disadvan-
tage for a specific health care provider if “lost” reimburse-
ment rates for (prolonged) MV are not compensated for by
reimbursement rates for ECCO2R treatment. Therefore
further prospective and larger clinical and economic stud-
ies on strategies to avoid MV by means of ECCO2R are
warranted to provide more evidence for rational decision
making both in clinical practice and on a health care sys-
tem level.
Conclusion
The additional costs of the use of ECCO2R to avoid IMV
in NIV failure in a mixed group of patients with acute-on-
chronic ventilatory insufficiency may be offset by a poten-
tial cost reduction through a shorter length of hospital
and ICU stay. Moreover, in patients with acute exacerba-
tion of COPD this novel treatment strategy may not only
hold clinical advantages, but may even reduce overall re-
source utilization and treatment costs. However, the pre-
liminary and hypothesis-generating results of this pilot
study must be validated in larger, prospective, multicentre,
high quality randomised clinical trials not only evaluating
clinical benefits but also paralleled by evaluation of cost-
effectiveness applying a micro-costing approach.
Key message
Additional costs associated with the use of arterio-
venous extracorporeal carbon dioxide removal to avoid
invasive mechanical ventilation in patients with acute-
on-chronic ventilatory insufficiency failing non-invasive
ventilation may be offset by a potential cost reduction
through a shorter length of ICU and hospital stay.
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